SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Lescarden (LCAR)
An SI Board Since February 2000
Posts SubjectMarks Bans Symbol
3 0 0 LCAR
Emcee:  Harry Chmelynski Type:  Unmoderated
Introduction Market Data Compact
LCAR is engaged in research, testing, & development of medications for the control & cure of various diseases and the licencing of its technologies by other companies. LCAR has discovered & is primarily investigating Catrix(R).

For the 6 mos. ended 11/99, revenues rose from $3K to $117K, Net loss fell 24% to $183K. Results reflect a license fee earned due to the Co.'s agreement with ICN IBERICA, S.A., partially offset by higher administrative & office expenses.
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News